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Abstract
Mucopolysaccharidosis (MPS) IIIB is a lysosomal disease due to the deficiency of the
enzyme α-N-acetylglucosaminidase (NAGLU) required for heparan sulfate (HS) degrada-
tion. The disease is characterized by mild somatic features and severe neurological disor-
ders. Very little is known on the cardiac dysfunctions in MPS IIIB. In this study, we used the
murine model of MPS IIIB (NAGLU knockout mice, NAGLU-/-) in order to investigate the car-
diac involvement in the disease. Echocardiographic analysis showed a marked increase in
left ventricular (LV) mass, reduced cardiac function and valvular defects in NAGLU-/- mice as
compared to wild-type (WT) littermates. The NAGLU-/- mice exhibited a significant increase
in aortic and mitral annulus dimension with a progressive elongation and thickening of ante-
rior mitral valve leaflet. A severe mitral regurgitation with reduction in mitral inflow E-wave-to-
A-wave ratio was observed in 32-week-old NAGLU-/- mice. Compared toWTmice, NAGLU-/-
mice exhibited a significantly lower survival with increased mortality observed in particular
after 25 weeks of age. Histopathological analysis revealed a significant increase of myocar-
dial fiber vacuolization, accumulation of HS in the myocardial vacuoles, recruitment of inflam-
matory cells and collagen deposition within the myocardium, and an increase of LV fibrosis
in NAGLU-/- mice compared to WTmice. Biochemical analysis of heart samples from
affected mice showed increased expression levels of cardiac failure hallmarks such as cal-
cium/calmodulin-dependent protein kinase II, connexin43, α-smooth muscle actin, α-actinin,
atrial and brain natriuretic peptides, and myosin heavy polypeptide 7. Furthermore, heart
samples from NAGLU-/- mice showed enhanced expression of the lysosome-associated
membrane protein-2 (LAMP2), and the autophagic markers Beclin1 and LC3 isoform II (LC3-
II). Overall, our findings demonstrate that NAGLU-/- mice develop heart disease, valvular
abnormalities and cardiac failure associated with an impaired lysosomal autophagic flux.
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Introduction
Mucopolysaccharidoses (MPS) are a group of lysosomal storage diseases characterized by the
accumulation of glycosaminoglycans (GAGs) in various organs of affected patients [1]. The
storage defect is due to the absence of lysosomal enzymes involved in GAG catabolism. Deposi-
tion of GAGs in the heart of individuals with MPS causes cardiac dysfunctions [2]. Although
advances in MPS treatment, including enzyme replacement therapy [3], hematopoietic stem
cell transplantation [4] and gene therapy [5], have significantly improved the outcome of these
disorders, death from cardiac causes continues to be common among these patients. The car-
diac valves, usually mitral and aortic, the heart muscle itself and coronary arteries are charac-
teristically affected in MPS patients [6–9]. However, the onset and extent of cardiac
involvement varies depending upon the type of MPS. Children with MPS I show the earliest
and most severe cardiac disorders, whereas cardiac involvement in individuals with MPS VII
has been reported in adulthood [6] as well as in young individuals [10]. While cardiac involve-
ment in patients with MPS I, II and VI has been well described [9], less is known about heart
dysfunctions in MPS III.
MPS III includes four distinct diseases (A, B, C, D) due to the deficiency of enzymes
involved in heparan sulfate (HS) degradation; in particular, MPS IIIB (Sanfilippo type B syn-
drome) is due to the deficiency of the lysosomal enzyme α-N-acetylglucosaminidase
(NAGLU). Patients with MPS IIIB are characterized by profound mental retardation, behav-
ioral problems and death usually in the second decade, along with somatic manifestations that
are highly variable among the different phenotypes. Few studies have been reported on cardiac
disorders in MPS IIIB patients [2, 8].
In order to get more insight into cardiac involvement in MPS IIIB disease, in this study we
used the murine model of the disease obtained by NAGLU gene disruption (NAGLU knockout
mice, NAGLU-/-) [11]. These mice exhibit a massive increase in HS deposition in the liver and
kidney, and, at a lesser extent, in the lung, spleen, thymus and heart. Here, we investigated car-
diac morphology and function in NAGLU-/- mice compared to wild-type (WT) littermates
over time using cardiac ultrasound, and histological and biochemical analyses. Furthermore, as
an impairment of autophagy was found in embryonic fibroblasts and brain tissues from MPS
IIIA mice [12], in human skin fibroblasts fromMPS VI patients and in the liver, spleen, and
kidney tissues fromMPS VI rats [13], we also investigated the autophagic marker levels in the
heart tissues of NAGLU-/- mice in order to verify whether abnormal autophagy might be
involved in heart dysfunction in MPS IIIB.
Materials and Methods
Animals and Ethics Statement
Wild-type C57/BL6 mice (WT, n = 30) were purchased from the Jackson Laboratory. NAGLU
knockout mice (NAGLU-/-, n = 30) were obtained and genotyped as previously described [11,
14]. The mice included in the study were housed with no more than 5 per cage, maintained
under identical conditions of temperature (21±1°C), humidity (60±5%) and light/dark cycle,
and had free access to normal mouse chow. All experiments involving animals were conducted
with a protocol specifically approved for this study by the Animal Care and Use Committee of
the "Biotechnology Centre", AORN Cardarelli (Naples, Italy) and in accordance with the prin-
ciples and procedures outlined in the Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
For ultrasound echocardiografic studies, the mice (WT, n = 15 and NAGLU-/-, n = 15) were
anesthetized with an intraperitoneal (i.p.) injection of Tiletamine 5 ml/kg, Zolazepam 5 ml/kg
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(Zoletil 100) and Xylazine 5 mg/Kg (Sigma-Aldrich) in order to minimize any suffering of the
animals. For histological and biochemical analyses, immediately after echocardiographic imag-
ing, mice were anesthetized with an additional i.p. injection of the above drugs, and then eutha-
nized by cervical dislocation in compliance with the recommendations contained in the
American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals.
Hearts were collected, and processed as reported in the following paragraphs.
Regarding the survival study, 15 WT and 15 NAGLU-/- mice were used. We have deter-
mined that the humane endpoint of MPS IIIB mice varied from 8 to 12 months of age. We
monitored the conditions of the mice every day, at 12:00, and if during the monitoring period
the mice showed the symptoms of late-stage clinical manifestation, such as urine retention, rec-
tal prolapse, protruding penis and spinal curvature, they were anesthetized with an i.p. injec-
tion of the above drugs, and then humanely sacrificed by cervical dislocation in compliance
with the recommendations contained in the American Veterinary Medical Association
(AVMA) Guidelines for the Euthanasia of Animals, to minimize suffering. Wild-type control
mice were observed until they were 8 month old.
Transthoracic echocardiography
Cardiac function of MPS IIIB animals was non-invasively monitored by transthoracic echocar-
diography using the Vevo 2100 high-resolution imaging system (VisualSonics). Briefly, the
mice were anesthetized, and echocardiograms were performed with a 30-MHz RMV-707B
scanning head. Annulus dimensions were obtained in the parasternal long-axis view during
systole for semilunar valves, and the apical four-chamber view during diastole for atrioventric-
ular valves as previously described [15]. The aortic root measurements were obtained in a mod-
ified parasternal long-axis view during diastole. Doppler interrogation was performed on the
atrioventricular valve inflow in the apical four-chamber view, and semilunar valve outflow in
the parasternal long axis view to assess for stenosis and regurgitation using a sample volume
toggle to optimize the angle of interrogation. A modified parasternal long-axis view was
required in some cases to ensure ascertainment of the maximum velocity. Cardiac chamber
dimensions were measured, and ventricular function assessed from two-dimensional-directed
M-mode echocardiographic images obtained from the parasternal short-axis view, and Dopp-
ler images were obtained from the apical four chamber view in accordance with consensus
guidelines [16]. All measurements were obtained in triplicate and averaged.
Histology
Whole hearts isolated from 32-week-old mice (NAGLU-/-, n = 5 and WT, n = 5) were fixed
overnight in a bath of 4% aqueous buffered formalin, and processed for paraffin embedding.
Coronal sections (10 μm thick) containing both right and left ventricles were processed as pre-
viously described [17–18]. Sequential sections from each heart were stained with haematoxylin
and eosin (H&E) (Sigma-Aldrich), Masson's trichrome dye (Sigma-Aldrich) and periodic acid-
Schiff Alcian blue-PAS (Dako). All sections were examined on a light microscope (Leitz, DIA-
PLAN), and images were acquired with a digital camera (Digital JVC, TK-C1380).
Plastic embedded sections were obtained from heart tissue specimens of 32-week-old mice
fixed in 2.5% glutaraldehyde and postfixed in 1% osmium tetroxide in cacodylate buffer
(0.2 M, pH 7.4). Tissues were washed and dehydrated in a graded series of ethanol solutions,
cleared in propylene oxide, and embedded in Epon—Araldite resin. Semithin (0.5 μm) sections
were stained with toluidine blue and examined under a light microscope.
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Immunohistochemistry
Immunostaining was performed on heart sections of NAGLU-/- andWTmice using the follow-
ing dilution of the primary mouse monoclonal antibodies: CD3, 1:50 (Dako, clone F7.2.38);
CD4, 1:15 (Vision Bio-System, clone IF6); CD8, 1:30 (Dako, clone C8/144B) and CD68, 1:50
(Dako, clone KP-1). Paraffin-embedded tissue specimens were cut at 4 μm thick sections,
mounted on microscope slides, deparaffinized and then re-dehydrated. The deparaffinized
slides were then boiled by microwave for 12 min in citrate buffer (pH 6) and stained with pri-
mary antibodies over night. The immunoreactions were visualized using the mouse version of
the EnVision+ system (Dako) and diaminobenzidine (DAB). Sections were counterstained
with Mayer’s haematoxylin. In the corresponding negative control sections, the primary anti-
body was either omitted or replaced with normal serum.
RNA extraction and real-time PCR
Total RNA was extracted from several pieces of left ventricle (LV) frozen samples obtained
from the whole hearts of 32-week-old mice (NAGLU-/-, n = 5 andWT, n = 5) using the TRIzol
(Invitrogen) according to the manufacturer’s instruction. Oligo-dT first strand cDNAs were
synthesized using the SuperScript VILO cDNA Synthesis (Life Technologies) according to the
manufacturer’s instructions. mRNA expression was determined by quantitative real-time PCR
(RT-PCR) as previously described [19–20], using an IQ-5 multicolor RT-PCR detection system
(Bio-Rad) and a SYBR Green PCRMaster Mix (Bio-Rad). The primers used were: myosin
heavy polypeptide 7 (Myh7, β-MHC): forward 5’-CGGAAACTGAAAACGGAAAG-3’, reverse
5’-TCCTCGATCTTGTCGAACTTG-3’; atrial natriuretic peptide (ANP): forward 5’-CACA
GATCTGATGGATTTCAAGA-3’, reverse 5’-CCTCATCTTCTACCGGCATC-3’; brain natri-
uretic peptide (BNP): forward 5’-GTCAGTCGTTTGGGCTGTAAC-3’, reverse 5’-AGACCC
AGGCAGAGTCAGAA-3’; glyceraldehyde 3-phosphate dehydrogenase (GAPDH): forward
5’-TGCAGTGGCAAAGTGGAGATT-3’, reverse 5’-TCGCTCCTGGAAGATGGTGAT-3’. The
initial denaturation phase was 5 min at 95°C followed by an amplification phase detailed as fol-
lowing: denaturation at 95°C for 10 s; annealing at 60°C for 30 s; elongation at 72°C for 30 s;
detection at 72°C for 40 cycles. Relative expression was calculated with the 2-ΔΔCt method.
Protein extraction and immunoblot analysis
Total protein extracts were prepared from several pieces of LV frozen samples obtained from
the whole hearts of 32-week-old mice (NAGLU-/-, n = 5 and WT, n = 5). LV pieces were dis-
rupted by tissue homogenization (Tissue Master 125, OMNI Int.) and lysed in a buffer contain-
ing 150 mMNaCl, 50 mM Tris-HCl, pH 7,5, 1 mM EDTA, 1% v/v NP-40, 0.5% w/v
deoxycholate, 10 mMNaF, 10 mM Na2pyrophosphate, 2 mM phenylmethylsulfonyl fluoride
(PMSF), 2 oridehleupeptin, 2 eptin,aprotinin. Lysates were incubated on ice for 15 min, and
then centrifuged at 13000 rpm for 30 min at 4°C. The protein concentration of lysates was mea-
sured using a dye-binding protein assay kit (Bio-Rad) and a spectrophotometer reader at a
wavelength of 595 nm. Immunoblotting was performed using commercially available antibod-
ies: α-actinin (1:1000, mouse monoclonal, Sigma-Aldrich), α-smooth muscle actin (α-SMA)
(1:1000, mouse monoclonal, Sigma-Aldrich), Beclin1 (BCN1) (1:500, rabbit polyclonal, Santa
Cruz), calcium/calmodulin-dependent protein kinase II (CaMKII) (1:1000, mouse monoclonal,
Santa Cruz), connexin43 (Cx43) (1:500, rabbit polyclonal, Santa Cruz), lipidated isoform of
LC3 (LC3 II) (1:500, rabbit polyclonal, Novus Biological), lysosome-associated membrane pro-
tein 2 (LAMP2) (1:500, rabbit polyclonal, Pierce), tubulin (1:1000, mouse monoclonal, Sigma-
Aldrich). Secondary antibodies were purchased from Amersham Life Sciences Inc and used at
concentration of 1:3000. Bands were visualized by enhanced chemiluminescence (ECL;
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Amersham Life Sciences Inc.) according to the manufacturer’s instructions, and were quanti-
fied using densitometry. Each experiment was separately repeated at least three times, and den-
sitometric quantification was normalized versus tubulin protein levels.
Statistical analysis
Data are expressed as means ± standard deviation (SD). Statistical significance between groups
was assessed by Student's t test. For all analyses, a minimum value of p<0.05 was considered
significant. The survival curves were constructed using Kaplan-Meier probability estimation,
and survival was compared using a log rank survivor function. All the analyses were performed
with GraphPad Prism version 5.01 (GraphPad Software).
Results and Discussion
NAGLU-/- mice show reduced cardiac function and valvular defects
The progressive accumulation of undegraded GAGs in MPS results in multiple organ system
dysfunctions that vary depending on the particular GAG deposited and the specific enzyme
deficiency. Cardiac involvement has been reported in MPS diseases, although it has been better
characterized for MPS I, II, and VI, and it significantly contributes to early mortality of these
patients [2]. The cardiac causes of death include heart failure, sudden death from arrhythmias,
pulmonary hypertension, and coronary occlusion [21–24]. In order to investigate cardiac
involvement in MPS IIIB, we evaluated heart morphology and cardiac function in the murine
model of MPS IIIB (NAGLU-/-) compared to wild-type (WT) mice starting from 16 to 32
weeks of age by serial echocardiograms over time. Interestingly, a decreased percentage of LV
fractional shortening (FS%) was observed in NAGLU-/- mice compared to WT animals from
16 weeks to 32 weeks of age (Fig 1A and 1B). A significant reduction in LV FS% started from
24 weeks of age and was maintained up to 32 weeks of age.
Since cardiac valve pathology is the most prominent cardiac manifestation (60–90%) of
patients with MPS [2, 6–9, 24], we sought to determine heart valve morphology and dimen-
sions by echocardiography in both NAGLU-/- and WT mice as a function of age at serial time
points. Although no differences were found in the right chamber valves and aortic root dimen-
sions between NAGLU-/- and WT hearts at different time points, NAGLU-/- mice exhibited a
significant increase in the aortic annulus dimension and mitral annulus dimension and a pro-
gressive elongation and thickening of the anterior mitral valve leaflet compared to WT mice
(Fig 1C). Accordingly, Doppler analysis of the mitral flow showed that NAGLU-/- mice at 32
weeks of age exhibited a significant downward regurgitant jet at the mitral orifice compared to
WT mice (Fig 1D). Moreover, severe mitral regurgitation was confirmed by the reduction of
the mitral inflow E-wave to A-wave ratio observed in NAGLU-/- mice at 32 weeks of age com-
pared to age-matched WT (Fig 1E). Consistently with our findings, a retrospective study on 99
patients with MPS reports that mitral regurgitation occurs more frequently in types I, II and III
while aortic regurgitation is more common in MPS II and IV, and both mitral and aortic regur-
gitation showed a positive association with age [7].
Finally, a significant increase in the LV weight (LVW) to body weight (BW) ratio (LVW/
BW) was detected in 32-week-old NAGLU-/- mice compared to WT mice (Fig 1F) along with a
marked increase of heart dimension (Fig 1G). Reports of ventricular dilatation in MPS are still
limited [24–25]. Dilatation in MPS VI patient group was explained mainly by mitral-valve
regurgitation [9]. Primary regurgitation causes LV remodeling and dilatation. Generally MPS
patients exhibit an increase in geometric features that has been ascribed in part to the compen-
satory mechanism caused by the mitral regurgitation and in part because of the accumulation
of storage material [9].
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Fig 1. Echocardiographic andmorphometric analysis of NAGLU-/- mice. A. Cumulative data of % fractional shortening (FS%) of WT and NAGLU-/- mice
from 16 weeks to 32 weeks of age (*p<0.05). B. Representative M-mode echocardiographic tracings of WT and NAGLU-/- mice at 16 weeks and 32 weeks of
age.C. Cumulative data of mitral annulus dimension (mm) of WT and NAGLU-/- mice from 16 weeks to 32 weeks of age (*p<0.05).D. Doppler analysis of
mitral valve regurgitation of WT and NAGLU-/- mice at 32 weeks of age. E. Bar graphs showing mitral inflow E-wave to A-wave ratio in WT and NAGLU-/- mice
at 32 weeks of age (*p<0.05). F. Bar graphs showing left ventricle weight to body weight ratio (LVW/BW) in WT and NAGLU-/- mice at 32 weeks of age
(*p<0.05).G. Representative gross morphology of whole hearts from 32-week-old WT and NAGLU-/- mice.
doi:10.1371/journal.pone.0131662.g001
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To assess whether the observed differences in cardiac structures between NAGLU-/- and
WTmice would translate in survival benefit, survival rate was monitored for over 30 weeks
after birth in both groups of mice. Compared to WT mice, NAGLU-/- mice exhibited a signifi-
cantly lower survival with increased mortality observed in particular after 25 weeks of age
(S1 Fig). Overall, these results indicate that NAGLU-/- mice develop cardiac dysfunction in
age-dependent manner influencing the survival rate of murine MPS IIIB.
NAGLU-/- mice show cardiac valve thickening
The echocardiographic findings prompted us to carry out a histological analysis of cardiac
valve structure. The analysis of both aortic and mitral valve morphology in NAGLU-/- and WT
mice showed aortic and mitral valve defects in NAGLU-/- at 32 weeks of age (Fig 2). In particu-
lar, NAGLU-/- mice exhibited a significant aortic (Fig 2A) and mitral (Fig 2B) cuspid thicken-
ing as shown by H&E staining. Mitral and aortic valve thickening has been reported in canine
MPS VII [26] as well as in a MPS I and VI mouse models [27–28]. Our results, in agreement
with echocardiographic and Doppler analyses, indicate that the alterations in the valve mor-
phology in NAGLU-/- mice are associated with a progressive reduction in cardiac function over
time and that abnormal valve morphology and function produce both diastolic and systolic
dysfunctions, suggesting that severe mitral regurgitation is the "primum movens" of cardiac
dysfunction in MPS IIIB mice.
NAGLU-/- mice show myocardial vacuolization, inflammation, and
fibrosis
In order to further investigate the features of cardiac disease in the MPS IIIB mouse model, a
histopathological analysis of the myocardium of NAGLU-/- mice was performed. This analysis
revealed a significant increase in myocardial fiber vacuolization compared to WT mice, as
shown by H&E staining (Fig 3). Lysosomal storage and cellular vacuolization was also qualita-
tively evaluated by bright-field microscopy on plastic embedded semithin section stained by
toluidine blue revealing at higher resolution the presence of vacuoles within the myocardial
fibers of MPS IIIB mice (Fig 3). Furthermore, Alcian blue-PAS staining shows the accumula-
tion of HS in the myocardial vacuoles of NAGLU-/- mice as indicated by areas of blue color
(Fig 3). The only GAG accumulated in NAGLU-/- mouse tissues is represented by HS due to
the specific enzymatic defect that characterizes MPS IIIB disease from other MPS syndromes
in which accumulation of GAGs is mixed [1, 11]. Thus, the storage of HS may represent the
main cause of valve defects and myocardial dysfunction in MPS IIIB mice.
To investigate whether affected myocardium of NAGLU-/- mice presents increased inflam-
mation and fibrosis, features often related to the cardiac failure, the presence of inflammatory
infiltrates and fibrosis was evaluated respectively by H&E and Masson's trichrome staining
(Fig 4). NAGLU-/- mice exhibited a significant recruitment of inflammatory cells within
the myocardium labeled by the specific inflammatory markers CD3, CD4, CD8 and CD68
(S2 Fig). Moreover, the staining with CD68 confirmed the presence of vacuoles within the mac-
rophages (arrows in S2 Fig), in accordance with literature data [11]. Concerning fibrosis of
affected mice, collagen deposition was localized near the valves and at lower extent in the myo-
cardium (S3 Fig). Many reports deal with an abnormal content or structure of collagen in car-
diac tissues of MPS animal models and patients [2, 8, 25–26, 28–32]. Our results are consistent
with previous findings showing myocardial fibrosis in the murine models of MPS I [28] and
MPS II [29], and the deposition of large amounts of collagen in the valves and myocardium of
patients affected by Hurler syndrome [30].
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Overall, these results demonstrate, for the first time, that NAGLU gene deletion causes in
the murine model of MPS IIIB specific myocardial structure alterations due to HS vacuoliza-
tion, increased inflammation and fibrosis.
NAGLU-/- mice show increased levels of cardiac failure markers
In order to confirm the ecocardiographic and histopathological data of the cardiac involvement
in the MPS IIIB mouse model at the molecular level, biochemical analyses of LV samples from
Fig 2. Histological analysis of cardiac valves thickening. A. Representative images of haematoxylin and eosin (H&E) of aortic valve sections fromWT
and NAGLU-/- hearts at 32 weeks of age (20x magnification). B. Representative images of haematoxylin and eosin (H&E) of mitral valve sections fromWT
and NAGLU-/- hearts at 32 weeks of age (20x magnification). Scale bars: 20 μm.
doi:10.1371/journal.pone.0131662.g002
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Fig 3. Histological analysis of myocardial vacuolization. Representative H&E, Toluidine blue and Alcian blue-PAS staining of LV tissues form heart of
32-week-old WT and NAGLU-/- mice (100x magnification) shows vacuolization and deposition of HS into vacuoles. Arrows indicate vacuoles within
myocardial fibers in the H&E (upper panel) and toluidine blue (middle panel), and HS accumulation in the Alcian blue-PAS staining (lower panel). Scale bars:
20 μm.
doi:10.1371/journal.pone.0131662.g003
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NAGLU-/- and WT mice were carried out. First, we found an enhanced expression of hypertro-
phy and fibrosis markers in heart tissues from NAGLU-/- mice compared to WT littermates, as
demonstrated by increased myocardial protein levels of CaMKII [33], Cx43 [34], α-actinin
[35] and α-SMA [18] (Fig 5A). Moreover, LV samples from NAGLU-/- mice were characterized
by a significant increase in the mRNA levels of ANP, BNP and Myh7 (Fig 5B), hallmarks of
cardiac dysfunctions and failure [36–37].
Overall, these results are consistent with the cardiac dysfunctions detected by echocardiog-
raphy and histology in affected mice, and demonstrate that NAGLU gene deletion causes spe-
cific myocardial structure alterations over time leading to cardiac failure.
Autophagy impairment in the heart of NAGLU-/- mice
Alterations in the autophagic process have recently been suggested as a pathogenic mechanism
common to a variety of lysosomal storage diseases including some MPS IIIA and VI types [12–
13]. However, the block of autophagy in MPS has never been studied in connection with
Fig 4. Histological analysis of myocardial inflammation and fibrosis in NAGLU-/- mice.Representative H&E staining for inflammatory infiltrate and
Masson's trichrome staining for fibrosis in LV tissues fromWT and NAGLU-/- mice (40x magnification). Arrow indicates inflammatory infiltrates within
myocardial fibers and asterisk (*) indicates fibrosis within myocardial fibers. Scale bars: 20 μm.
doi:10.1371/journal.pone.0131662.g004
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cardiac problems. Here, we investigated whether an impairment of autophagy might be associ-
ated to cardiac dysfunctions in NAGLU-/- mice together with the lysosomal defects. To this
purpose, we first investigated cardiac lysosomal involvement in NAGLU-/- mice by evaluating
the protein levels of the lysosomal marker LAMP2 [38]. Cardiac levels of LAMP2 were signifi-
cantly increased in NAGLU-/- mice compared to WT mice, as shown by Western blotting anal-
ysis (Fig 6). We found in LV samples of NAGLU-/- mice an increased expression of Beclin1
(BCN1, homologue of yeast ATG6), a protein of the Class III phosphatidylinositol 3 kinase
(PI3K) complex that mediates the early phase of autophagy [39] (Fig 6). BCN1 protein is
involved in the formation of autophagosome. The microtubule-associated protein I light chain
(LC3-I, homologue of yeast ATG8) is also implicated in this process; LC3-I is cleaved at its
Fig 5. Biochemical evaluation of cardiac failure markers in NAGLU-/- mice. A. Representative immunoblot and densitometric analysis of CaMKII, Cx43,
α-actinin and α-SMA protein levels in WT and NAGLU-/- heart samples at 32 weeks of age (*p<0.05). B. Real-time PCR analysis of ANP, BNP and Myh7
mRNA levels in WT and NAGLU-/- hearts at 32 weeks of age (*p<0.05).
doi:10.1371/journal.pone.0131662.g005
Cardiac Disease in the Murine Model of Mucopolysaccharidosis IIIB
PLOS ONE | DOI:10.1371/journal.pone.0131662 July 6, 2015 11 / 15
carboxy-terminal and further modified to the lipid-conjugated LC3-II which is associated to
autophagosome membranes [40]. LC3-II levels are reflective of autophagosome abundance.
Western blotting analysis of mouse heart samples showed that LC3-II expression levels were
significantly increased in cardiac samples from NAGLU-/- mice compared to WT littermates
(Fig 6). These results indicate that the autophagic process is dysfunctional in the heart of
NAGLU-/- mice, thus suggesting that dysregulated autophagic capacity can have a detrimental
impact in heart tissue, and might represent an important factor contributing to the cardiac dis-
ease in MPS IIIB. Indeed, in the heart of NAGLU-/- mice, lysosomal accumulation of HS, due
to NAGLU enzyme deficiency, activates autophagy, as demonstrated by increased BCN1
expression levels, but the formed autophagosome cannot be cleared, as shown by the enhanced
expression of LC3-II in cardiac samples of NAGLU-/- mice as compared to WT mice. However,
further investigations are needed to establish whether the substrate accumulation is the pri-
mary mediator of abnormal lysosomal autophagy, and whether the accumulation of autopha-
gosomes rather than the block of the autophagosome-lysosome fusion is responsible for
autophagy impairment in the heart of affected mice.
Conclusions
This study addresses for the first time the cardiac dysfunction in MPS IIIB. Our results demon-
strate that NAGLU-/- mice develop abnormal valve morphology and function in an age-depen-
dent manner in association with increased myocardial vacuolization, inflammation and
fibrosis. Furthermore, our data showing a dysregulated lysosomal autophagy in the cardiac tis-
sues of NAGLU-/- mice suggest that an abnormal autophagic pathway may represent an impor-
tant factor contributing to cardiac disease in the murine model of MPS IIIB, and presumably
this holds true also for human patients. An in-depth understanding of the pathophysiology of
heart disease in MPS IIIB is essential for adequate evaluations and timely management of these
patients to improve clinical outcomes and quality of life. Our findings could be relevant in the
screening of new therapies for the treatment of MPS IIIB disease.
Fig 6. Evaluation of lysosomal and autophagy markers in NAGLU-/- hearts.Representative immunoblot and densitometric analysis of LAMP2, BCN1
and LC3-II protein levels in WT and NAGLU-/- hearts at 32 weeks of age (*p<0.05).
doi:10.1371/journal.pone.0131662.g006
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Supporting Information
S1 Fig. Kaplan-Meier cumulative survival analysis of WT and NAGLU-/- mice (p<0.05).
(TIF)
S2 Fig. Immunostaining of individual immune cells in serial sections of NAGLU-/- heart.
Sections were stained with anti-sera raised against CD3, CD4, CD8 and CD68. All images were
acquired at 40x magnification. Scale bars: 20 μm.
(TIF)
S3 Fig. Localization of the fibrotic area near the valves of NAGLU-/- heart. Lower magnifica-
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